Jose Canseco and Human Genetic Engineering
By Osagie Obasogie,
Cincinnati Enquirer
| 10. 21. 2005
Will He Be Right Again?
Recently, Jose Canseco and I were guests on a talk show to discuss gene doping, the genetic equivalent to anabolic steroids - a way to "juice up" to gain a competitive edge. It is possible that in the next few years athletes will be able to enhance their performance by altering their genetic make-ups. Canseco argued that gene doping "is definitely the next big step in evolution." Genetic enhancement, he said, "goes way beyond sports. Imagine an army of a million individuals who can out-think, out-use the environment in the sense of less food, more reaction time, better vision, better physical reaction . . . (T)he human race . . . is going to evolve and no one's gonna stop it."
It's easy to dismiss this as the ramblings of a B-list star struggling to keep himself in the limelight. Indeed, when Canseco released his now infamous "Juiced: Wild Times, Rampant 'Roids, Smash Hits, and How Baseball Got Big," this was most people's response. Yet we have been forced to swallow the bitter truthfulness of Canseco's pill. In the few...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...